Rockefeller Capital Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Rockefeller Capital Management's IBRX Position: Q3 2026 in Review
Rockefeller Capital Management reduced its ImmunityBio (IBRX) stake by 33% in Q3 2026, selling an estimated $15.5K and leaving 4,020 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3608.
Rockefeller Capital Management first reported a position in IBRX in Q2 2020 and has held it in 16 quarters since. The position peaked at $144K in Q2 2021. 400 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Rockefeller Capital Management held 4,020 shares of ImmunityBio worth $37.9K as of Q3 2026.
- Rockefeller Capital Management sold 1,945 ImmunityBio shares in Q3 2026, an estimated $15.5K.
- ImmunityBio made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3608 holding.
- Rockefeller Capital Management first reported a position in ImmunityBio in Q2 2020 and has held it in 16 quarters since.
- Rockefeller Capital Management's ImmunityBio position peaked at $144K in Q2 2021.
- 400 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.